Your AI-Trained Oncology Knowledge Connection!

Video

Dr. Pollack on the Future Treatment Landscape for Sarcoma

Author(s):

Seth M. Pollack, MD

In Partnership With:

Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the future treatment paradigm of soft tissue sarcoma.

Seth M. Pollack, assistant professor, Division of Oncology, University of Washington, and attending physician, Seattle Cancer Care Alliance, discusses the future treatment paradigm of soft tissue sarcoma.

Regarding radiomics, Pollack envisions this novel treatment approach will have a role in the future.

Additionally, Pollack says that he is very excited for the field of sarcoma to move toward immunotherapy in the next 5 to 10 years. The data from SARC028, which investigated treatment with the PD-1 inhibitor pembrolizumab (Keytruda) holds promise for patients with pleomorphic undifferentiated sarcoma. Another ongoing clinical trial is exploring the combination trial of doxorubicin plus pembrolizumab, which also is exciting, Pollack adds.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Timothy S. Fenske, MD, MS
Sheela Rao, MBBS, MD, FRCP
Yufei Liu, MD, PhD
Seema A. Bhat, MD, a hematologist at The Ohio State University Comprehensive Cancer Center—James; as well as an assistant professor in the Department of Internal Medicine in the Division of Hematology at The Ohio State University
Jacob Moyer, BS, of Mayo Clinic
Alfred L. Garfall, MD
COOMBS
Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC
Alberto Montero, MD, MBA, CPHQ
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Related Content
R. Lor Randall, MD, FACS, David Linn Endowed Chair for Orthopaedic Surgery, chair, professor, Department of Orthopaedic Surgery, University of California Davis
March 21st 2025

Bioengineered Bone Marrow Model Reveals Potential New Strategies for Osteosarcoma Metastasis Control

Ryan Cassaday, MD, associate professor, Clinical Research Division, Fred Hutchinson Cancer Center; associate professor, Division of Hematology and Oncology, University of Washington School of Medicine
January 23rd 2025

Blinatumomab-Based Regimens Enhance and Refine the B-ALL Treatment Paradigm: With Ryan Cassaday, MD

Sara A. Hurvitz, MD, FACP, on HER2-positive brain cancer breast metastases
March 8th 2025

Systemic Therapies Are Now Preferred in Some Patients With HER2+ Breast Cancer Brain Metastases

Mazyar Shadman, MD, MPH, associate professor, Clinical Research Division, medical director, Cellular Immunotherapy, Fred Hutchinson Cancer Center
December 19th 2024

Zanubrutinib Leads the Way for Advancements in CLL Management: With Mazyar Shadman, MD, MPH

R. Lor Randall, MD, FACS, David Linn Endowed Chair for Orthopedic Surgery, chair, Department of Orthopedic Surgery, professor, Department of Orthopedic Surgery, University of California, Davis
March 6th 2025

Vimseltinib Stands Out as An Alternative to Surgery for Select Patients With Diffuse TGCT

SON-1010 in Solid Tumors | Image Credit: © magicmine – stock.adobe.com
March 5th 2025

Data Compilation Highlights Potential of SON-1010 to Enhance Therapeutic Efficacy in Solid Tumors